Several tumor cell surface markers are identified as specific and selective targets for anticancer therapy and present promising results as targeting agents in nanosystems such as CD44 [114,115], CD147 [116], CD133 [117,118], and CD321 [119]. Here, CD44 is linked to neoplasm.